보고서 요약(국문)

시장 개요
전 세계 혈액암 치료제 시장 규모는 2022년 630억 달러에 달했으며, 2030년까지 1,135억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 혈액암 치료제 시장은 2023년부터 2030년까지 연평균 7.8%의 성장률을 기록할 것으로 예상됩니다. 주요 시장 동향은 면역요법의 빠른 발전입니다.
예를 들어, 차세대 정밀 종양학 기업으로 더욱 스마트하고 조기에 암 치료를 가능하게 하는 Strata Oncology, Inc.는 2023년 4월 진행성 암 환자를 위한 최초의 분자 프로파일링 검사인 Strata Select를 출시했습니다.
이 새로운 진단 검사는 항 PD-1/PD-L1 체크포인트 억제제 면역요법의 효과를 예측하는 새로운 다변량 예측 바이오마커 알고리즘인 면역요법 반응 점수(Immunotherapy Response Score)를 특징으로 합니다. 혈액암 치료제는 화학요법, 표적 치료제, 면역 치료제, 보조 치료제 등 다양한 치료법을 포괄하며, 혈액과 골수 내 암세포의 성장을 특이적으로 표적 억제하도록 설계되었습니다.
이러한 약물들은 비정상적인 세포 과정을 방해하고, 암세포 증식을 억제하며, 세포자멸사를 유도하고, 정상적인 혈액 세포의 생성과 기능을 회복시키는 것을 목표로 합니다.
혈액암 치료제 시장은 혈액암 발병률 증가, 암 연구의 발전, 표적 치료제, 면역 치료제, 맞춤형 의학의 개발 등의 요인에 의해 성장하고 있습니다.
예를 들어, 2023년 5월, 암닐 파마슈티컬스(Amneal Pharmaceuticals, Inc.)는 뉴라스타(Neulasta)를 참조하는 바이오시밀러인 FYLNETRA를 사전 충전된 1회용 주사기 형태로 출시한다고 발표했습니다. FYLNETRA는 화학요법을 받는 환자들이 흔히 겪는 호중구 감소증 치료에 사용됩니다.

시장 동향
혈액암 발병률 증가
혈액암 발병률 증가는 예측 기간 동안 시장 점유율 성장을 견인하는 주요 요인입니다. 혈액암, 특히 백혈병, 림프종, 다발성 골수종과 같은 특정 유형의 혈액암은 고령층에서 더 흔하게 진단됩니다. 전 세계적으로 고령화가 진행됨에 따라 혈액암 발병률은 전반적으로 증가하고 있습니다.
특정 환경 요인에 대한 노출과 건강하지 못한 생활 습관은 혈액암 발병 위험을 높일 수 있습니다. 환경 요인에는 방사선, 특정 화학 물질, 살충제 및 산업 오염 물질에 대한 노출이 포함됩니다. 흡연, 과도한 음주, 좌식 생활과 같은 건강하지 못한 행동 또한 혈액암 발병에 기여할 수 있습니다.
높은 치료 비용 및 부작용
혈액암 치료제는 광범위한 연구 개발 노력과 복잡한 제조 및 테스트 과정으로 인해 가격이 높은 경우가 많습니다. 이러한 약물 비용은 환자, 의료 시스템 및 보험사에 상당한 재정적 부담을 줄 수 있습니다. 높은 치료 비용은 시장 성장에 영향을 미치고 환자의 혈액암 치료제 접근성을 저해할 수 있습니다.

혈액암 치료제는 피로, 메스꺼움, 구토, 탈모, 면역억제, 장기 독성 등 다양한 부작용을 유발할 수 있습니다. 이러한 부작용은 환자의 삶의 질과 치료 순응도에 상당한 영향을 미칠 수 있습니다. 부작용 관리 및 보조 치료 방안 개발은 환자 치료 결과 개선과 혈액암 치료제의 시장 수용도 향상에 중요한 요소입니다.
COVID-19 영향 분석
COVID-19 팬데믹은 혈액암 치료제 시장을 포함한 의료 산업 전반에 심각한 영향을 미쳤습니다. 혈액암 환자는 면역 체계가 약화되어 COVID-19 감염 시 중증으로 이어질 위험이 높기 때문에 취약한 집단으로 간주됩니다. 따라서 환자 관리 전략은 바이러스 노출을 최소화하도록 수정되었습니다.
혈액암 치료제 관련 연구 활동 중 일부는 COVID-19 관련 프로젝트로 일시적으로 우선순위가 낮아지거나 방향이 전환되었을 수 있습니다. 이러한 연구 초점의 변화는 혈액암 치료제 시장의 신약 개발 및 혁신 속도에 영향을 미칠 수 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 혈액암 치료제 시장에 상당한 영향을 미쳤습니다. 이 분쟁으로 인해 연구 기관 및 제약 회사의 연구 개발 협력이 저해될 수 있습니다. 신약 개발, 임상 시험 및 과학 교류 분야의 협력 노력이 저해되어 새로운 혈액암 치료제 개발 및 혁신 속도에 영향을 미칠 수 있습니다.
러시아와 우크라이나 간의 갈등은 혈액암 치료제 시장의 국제 협력 및 투자에 영향을 미칠 수 있습니다. 기업과 투자자들은 지정학적 위험과 불확실성으로 인해 이러한 시장에 신중하게 접근할 수 있으며, 이는 투자 및 협력의 둔화로 이어질 가능성이 있습니다.
세분화 분석
세계 혈액암 치료제 시장은 암 유형, 치료 유형, 투여 경로, 최종 사용자 및 지역별로 세분화됩니다.
암 유형별로는 백혈병 부문이 시장 점유율을 주도할 것으로 예상됩니다.
백혈병 시장은 2022년 세계 혈액암 치료제 시장의 35.8%를 차지할 것입니다. 백혈병은 혈액암 치료제 분야에서 광범위한 연구 개발 노력의 대상이었습니다. 다양한 백혈병 아형의 분자적 기반을 이해하는 데 상당한 진전이 이루어졌으며, 이는 표적 치료법과 면역 치료법 개발로 이어졌습니다.

예를 들어, 2023년 5월 미국-아일랜드 제약회사인 쇼라 온콜로지(Shorla Oncology)와 생명과학 산업에 상용화 서비스를 제공하는 선도 기업인 에버사나(EVERSANA)는 1세 이상 성인 및 소아 환자의 T세포 급성 림프구성 백혈병(T-ALL) 및 T세포 림프구성 림프종(T-LBL) 치료를 위한 자사의 항암제 넬라라빈 주사제(Nelarabine Injection)의 상용화를 발표했습니다.
지역 분석
북미는 주요 기업과 선진 의료 인프라를 바탕으로 가장 큰 시장 점유율을 차지하고 있습니다.
북미는 주요 기업과 선진 의료 인프라를 보유하고 있어 2022년 혈액암 치료제 시장에서 41.3%의 시장 점유율을 차지했습니다. 북미는 잘 구축된 병원, 연구 기관, 종양 센터를 포함한 선진 의료 인프라를 자랑합니다.
이 지역은 혈액암 환자들이 진단, 치료 및 사후 관리에 쉽게 접근할 수 있도록 하는 강력한 의료 시스템을 갖추고 있습니다. 최첨단 의료 시설, 고급 진단 기술 및 전문 의료진의 가용성은 혈액암 치료제 수요를 뒷받침하고 시장 성장을 견인합니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd 및 UCB SA가 있습니다.
보고서 구매 이유

• 암 유형, 치료 유형, 투여 경로, 최종 사용자 및 지역별 글로벌 혈액암 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 혈액암 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 혈액암 치료제 시장 보고서는 약 54개의 표, 46개의 그림, 그리고 195페이지 분량으로 구성됩니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Blood Cancer Drugs Market size reached US$ 63 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 113.5 billion by 2030. The Global Blood Cancer Drugs Market is expected to exhibit a CAGR of 7.8% during the forecast period 2023-2030. The key market trend is the rapid advancements of immunotherapies.
For instance, in April 2023, Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select, a first-of-its-kind molecular profiling test for patients with advanced cancer.
The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit. Blood cancer drugs encompass diverse therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies, and supportive care medications, designed to specifically target and inhibit the growth of cancerous cells in the blood and bone marrow.
These drugs aim to disrupt abnormal cellular processes, suppress cancer cell proliferation, induce apoptosis, and restore normal blood cell production and function.
The blood cancer drugs market is driven by factors such as the increasing prevalence of blood cancers, advancements in cancer research, development of targeted therapies, immunotherapies, and personalized medicine.
For instance, in May 2023, Amneal Pharmaceuticals, Inc. announced the commercial launch of FYLNETRA, a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy.
Market Dynamics
Increasing prevalence of blood cancers
The increasing prevalence of blood cancers is the major factor driving the market share during the forecast period. Blood cancers, particularly certain types such as leukemia, lymphoma, and multiple myeloma, are more commonly diagnosed in older individuals. As the global population continues to age, the overall incidence of blood cancers increases.
Exposure to certain environmental factors and unhealthy lifestyle choices can increase the risk of developing blood cancers. Environmental factors include exposure to radiation, certain chemicals, pesticides, and industrial pollutants. Unhealthy behaviors like smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to the development of blood cancers.
High cost and side effects of treatment
Blood cancer drugs often come with a high price tag due to the extensive research and development efforts involved and the complexity of manufacturing and testing processes. The cost of these drugs can pose a significant financial burden on patients, healthcare systems, and payers. The high cost of treatment can impact market growth and hinder patient access to blood cancer drugs.
Blood cancer drugs can cause various adverse effects, including fatigue, nausea, vomiting, hair loss, immunosuppression, and organ toxicity. These side effects can significantly impact patients' quality of life and treatment adherence. Managing side effects and developing supportive care measures are important considerations in improving patient outcomes and market acceptance of blood cancer drugs.
COVID-19 Impact Analysis
The COVID-19 pandemic has profoundly impacted the healthcare industry, including the blood cancer drugs market. Blood cancer patients are considered vulnerable due to their compromised immune systems and higher risk of severe COVID-19 outcomes. As a result, patient management strategies have been modified to minimize exposure to the virus.
Some research activities related to blood cancer drugs may have been temporarily deprioritized or redirected towards COVID-19-related projects. This shift in research focus may impact the pace of drug development and innovation in the blood cancer drugs market
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict has significantly impacted the blood cancer drugs market. The conflict may disrupt research and development collaboration in institutions and pharmaceutical companies. Collaborative efforts in drug discovery, clinical trials, and scientific exchange may be hampered, impacting the pace of innovation and development of new blood cancer drugs.
The conflict between Russia and Ukraine may impact international collaborations and investments in the blood cancer drugs market. Companies and investors may approach these markets with caution due to geopolitical risks and uncertainties, potentially leading to a slowdown in investments and collaborations.
Segment Analysis
The Global Blood Cancer Drugs Market is segmented based on cancer type, therapy type, route of administration, End User, and region.
Based on cancer type, the leukemia segment is expected to dominate the market share
The leukemia market will hold 35.8% of the global blood cancer drugs market share in 2022. Leukemia has been the subject of extensive research and development efforts in the field of blood cancer drugs. Significant advancements have been made in understanding the molecular basis of different leukemia subtypes, leading to the development of targeted therapies and immunotherapies.
For instance, in May 2023, Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA, a leading provider of commercialization services to the life science industry, announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older.
Geographical Analysis
North America holds the largest market share due to the presence of key players and advanced healthcare infrastructure
North America holds the 41.3% market share for the blood cancer drugs market in 2022 due to the presence of key players and advanced healthcare infrastructure in the region. North America boasts advanced healthcare infrastructure, including well-established hospitals, research institutions, and oncology centers.
The region has a robust healthcare system that facilitates access to diagnosis, treatment, and follow-up care for blood cancer patients. The availability of state-of-the-art medical facilities, advanced diagnostic technologies, and specialized healthcare professionals supports the demand for blood cancer drugs and drives market growth.
Competitive Landscape
The major global players in the market include Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.
Why Purchase the Report?
• To visualize the Global Blood Cancer Drugs Market segmentation based on cancer type, therapy type, route of administration, End User, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of blood cancer drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Blood Cancer Drugs Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Therapy Type
3.3. Snippet by Route of Administration
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of blood cancers
4.1.1.2. Development of targeted therapies and immunotherapies
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.2.2. Side effects associated with treatment
4.1.3. Opportunity
4.1.3.1. Advancements in cancer research
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Cancer Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Leukemia*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Myeloma
7.4. Non-Hodgkin Lymphoma
7.5. Hodgkin Lymphoma
8. By Therapy Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.1.2. Market Attractiveness Index, By Therapy Type
8.2. Chemotherapy*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Radiation Therapy
8.4. Immunotherapy
8.5. Targeted Therapy
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Ambulatory Surgical Centers
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Amgen Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. AstraZeneca Plc
13.3. Takeda Pharmaceutical Company Ltd
13.4. Bayer AG
13.5. Celgene Corporation
13.6. Eli Lilly
13.7. Bristol-Myers Squibb Company
13.8. Gilead Sciences Inc.
13.9. Daiichi Sankyo Company Ltd
13.10. UCB SA
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Amgen Inc., 4.	Key Developments, AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, UCB SA

표 목록 (Tables)

List of Tables Table 1 Global Blood Cancer Drugs Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Blood Cancer Drugs Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Blood Cancer Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Blood Cancer Drugs Market Value, By End user, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Blood Cancer Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Blood Cancer Drugs Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Blood Cancer Drugs Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 8 Global Blood Cancer Drugs Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Blood Cancer Drugs Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 10 Global Blood Cancer Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Blood Cancer Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 12 Global Blood Cancer Drugs Market Value, By End user, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Blood Cancer Drugs Market Value, By End user, 2022-2031 (US$ Million)

Table 14 Global Blood Cancer Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Blood Cancer Drugs Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Blood Cancer Drugs Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 17 North America Blood Cancer Drugs Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 18 North America Blood Cancer Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 North America Blood Cancer Drugs Market Value, By End user, 2022-2031 (US$ Million)

Table 20 North America Blood Cancer Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Blood Cancer Drugs Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 22 South America Blood Cancer Drugs Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 23 South America Blood Cancer Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 South America Blood Cancer Drugs Market Value, By End user, 2022-2031 (US$ Million)

Table 25 South America Blood Cancer Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Blood Cancer Drugs Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 27 Europe Blood Cancer Drugs Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 28 Europe Blood Cancer Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 29 Europe Blood Cancer Drugs Market Value, By End user, 2022-2031 (US$ Million)

Table 30 Europe Blood Cancer Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Blood Cancer Drugs Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Blood Cancer Drugs Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Blood Cancer Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Blood Cancer Drugs Market Value, By End user, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Blood Cancer Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East & Africa Blood Cancer Drugs Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 37 Middle East & Africa Blood Cancer Drugs Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 38 Middle East & Africa Blood Cancer Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 39 Middle East & Africa Blood Cancer Drugs Market Value, By End user, 2022-2031 (US$ Million)

Table 40 Amgen Inc.: Overview

Table 41 Amgen Inc.: Product Portfolio

Table 42 Amgen Inc.: Key Developments

Table 43 AstraZeneca Plc: Overview

Table 44 AstraZeneca Plc: Product Portfolio

Table 45 AstraZeneca Plc: Key Developments

Table 46 Takeda Pharmaceutical Company Ltd: Overview

Table 47 Takeda Pharmaceutical Company Ltd: Product Portfolio

Table 48 Takeda Pharmaceutical Company Ltd: Key Developments

Table 49 Bayer AG: Overview

Table 50 Bayer AG: Product Portfolio

Table 51 Bayer AG: Key Developments

Table 52 Celgene Corporation: Overview

Table 53 Celgene Corporation: Product Portfolio

Table 54 Celgene Corporation: Key Developments

Table 55 Eli Lilly: Overview

Table 56 Eli Lilly: Product Portfolio

Table 57 Eli Lilly: Key Developments

Table 58 Bristol-Myers Squibb Company: Overview

Table 59 Bristol-Myers Squibb Company: Product Portfolio

Table 60 Bristol-Myers Squibb Company: Key Developments

Table 61 Gilead Sciences Inc.: Overview

Table 62 Gilead Sciences Inc.: Product Portfolio

Table 63 Gilead Sciences Inc.: Key Developments

Table 64 Daiichi Sankyo Company Ltd: Overview

Table 65 Daiichi Sankyo Company Ltd: Product Portfolio

Table 66 Daiichi Sankyo Company Ltd: Key Developments

Table 67 UCB SA: Overview

Table 68 UCB SA: Product Portfolio

Table 69 UCB SA: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 2 Global Blood Cancer Drugs Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 3 Global Blood Cancer Drugs Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 4 Global Blood Cancer Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 5 Global Blood Cancer Drugs Market Share, By End user, 2022 & 2031 (%)

Figure 6 Global Blood Cancer Drugs Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Blood Cancer Drugs Market Y-o-Y Growth, By Cancer Type, 2022-2030 (%)

Figure 8 Leukemia Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 9 Myeloma Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 10 Non-Hodgkin Lymphoma Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 11 Hodgkin Lymphoma Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 12 Global Blood Cancer Drugs Market Y-o-Y Growth, By Therapy Type, 2022-2030 (%)

Figure 13 Chemo Therapy Type in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 14 Radiation Therapy Type in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 15 Immuno Therapy Type in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 16 Targeted Therapy Type in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 17 Others Therapy Type in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 18 Global Blood Cancer Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 19 Oral Route of Administration in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 20 Parenteral Route of Administration in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 21 Others Route of Administration in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure22 Global Blood Cancer Drugs Market Y-o-Y Growth, By End user, 2022-2030 (%)

Figure 23 Hospitals End user in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 24 Specialty Clinics End user in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 25 Ambulatory Surgical Centers End user in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 26 Others End user in Global Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 27 Global Blood Cancer Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 29 Asia-Pacific Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 30 Europe Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 31 South America Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 32 Middle East and Africa Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 33 North America Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 34 North America Blood Cancer Drugs Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 35 North America Blood Cancer Drugs Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 36 North America Blood Cancer Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 37 North America Blood Cancer Drugs Market Share, By End user, 2022 & 2031 (%)

Figure 38 North America Blood Cancer Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 39 South America Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 40 South America Blood Cancer Drugs Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 41 South America Blood Cancer Drugs Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 42 South America Blood Cancer Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 43 South America Blood Cancer Drugs Market Share, By End user, 2022 & 2031 (%)

Figure 44 South America Blood Cancer Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 45 Europe Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 46 Europe Blood Cancer Drugs Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 47 Europe Blood Cancer Drugs Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 48 Europe Blood Cancer Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 49 Europe Blood Cancer Drugs Market Share, By End user, 2022 & 2031 (%)

Figure 50 Europe Blood Cancer Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 51 Asia-Pacific Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 52 Asia-Pacific Blood Cancer Drugs Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 53 Asia-Pacific Blood Cancer Drugs Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 54 Asia-Pacific Blood Cancer Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 55 Asia-Pacific Blood Cancer Drugs Market Share, By End user, 2022 & 2031 (%)

Figure 56 Asia-Pacific Blood Cancer Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 57 Middle East & Africa Blood Cancer Drugs Market Value, 2022-2031 (US$ Million)

Figure 58 Middle East & Africa Blood Cancer Drugs Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 59 Middle East & Africa Blood Cancer Drugs Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 60 Middle East & Africa Blood Cancer Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 61 Middle East & Africa Blood Cancer Drugs Market Share, By End user, 2022 & 2031 (%)

Figure 62 Amgen Inc.: Financials

Figure 63 AstraZeneca Plc: Financials

Figure 64 Takeda Pharmaceutical Company Ltd: Financials

Figure 65 Bayer AG: Financials

Figure 66 Celgene Corporation: Financials

Figure 67 Eli Lilly: Financials

Figure 68 Bristol-Myers Squibb Company: Financials

Figure 69 Gilead Sciences Inc.: Financials

Figure 70 Daiichi Sankyo Company Ltd: Financials

Figure 71 UCB SA: Financials

세계 혈액암 치료제 시장 – 2023-2030

Global Blood Cancer Drugs Market - 2023-2030